PortalPublikationenIncidence of Second Primary Malignancies after Autologous Tr...

Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents

Standard

Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents. / Sahebi, Firoozeh; Iacobelli, Simona; Sbianchi, Giulia; Koster, Linda; Blaise, Didier; Reményi, Péter; Russell, Nigel H; Ljungman, Per; Kobbe, Guido; Apperley, Jane; Trneny, Marek; Krejci, Marta; Wiktor-Jedrzejczak, Wieslaw; Sanchez, James F; Schaap, Nicolaas; Isaksson, Cecilia; Lenhoff, Stig; Browne, Paul; Scheid, Christof; Wilson, Keith M O; Yakoub-Agha, Ibrahim; González Muñiz, Soledad; Schönland, Stefan; Morris, Curly; Garderet, Laurent; Kröger, Nicolaus.

in: BIOL BLOOD MARROW TR, Jahrgang 24, Nr. 5, 05.2018, S. 930-936.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Sahebi, F, Iacobelli, S, Sbianchi, G, Koster, L, Blaise, D, Reményi, P, Russell, NH, Ljungman, P, Kobbe, G, Apperley, J, Trneny, M, Krejci, M, Wiktor-Jedrzejczak, W, Sanchez, JF, Schaap, N, Isaksson, C, Lenhoff, S, Browne, P, Scheid, C, Wilson, KMO, Yakoub-Agha, I, González Muñiz, S, Schönland, S, Morris, C, Garderet, L & Kröger, N 2018, 'Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents', BIOL BLOOD MARROW TR, Jg. 24, Nr. 5, S. 930-936. https://doi.org/10.1016/j.bbmt.2018.01.006

APA

Sahebi, F., Iacobelli, S., Sbianchi, G., Koster, L., Blaise, D., Reményi, P., Russell, N. H., Ljungman, P., Kobbe, G., Apperley, J., Trneny, M., Krejci, M., Wiktor-Jedrzejczak, W., Sanchez, J. F., Schaap, N., Isaksson, C., Lenhoff, S., Browne, P., Scheid, C., ... Kröger, N. (2018). Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents. BIOL BLOOD MARROW TR, 24(5), 930-936. https://doi.org/10.1016/j.bbmt.2018.01.006

Vancouver

Sahebi F, Iacobelli S, Sbianchi G, Koster L, Blaise D, Reményi P et al. Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents. BIOL BLOOD MARROW TR. 2018 Mai;24(5):930-936. https://doi.org/10.1016/j.bbmt.2018.01.006

Bibtex

@article{dac89e5725f943a9837b41fcbb772687,
title = "Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents",
abstract = "The advent of novel agents for multiple myeloma (MM) is cause for a re-examination of the incidence of second primary malignancies (SPMs). We examined the SPM rate in MM patients who were enrolled in the prospective observational CALM (Collaboration to Collect Autologous Transplant outcome in Lymphoma and Myeloma) study. Between 2008 and 2012, 3204 patients with MM underwent a first autologous hematopoietic stem cell transplantation. Plerixafor was used as a mobilizing agent for patients with poor (or potentially poor) stem cell mobilization as defined by the respective centers. A total of 135 patients developed SPMs, with a cumulative incidence of 5.3% (95% confidence interval, 4.4 to 6.3) at 72 months. Ninety-four patients developed solid tumors, 30 developed hematologic malignancies, and 11 developed an SPM of an unknown type. The cumulative incidence of known hematologic and solid malignancies were 1.4% and 3.6%, respectively, at 72 months. In a univariate analysis, use of radiotherapy, type of induction regimen, hematopoietic stem cell dose, poor mobilizer status, plerixafor use, and sex did not influence the cumulative incidence of SPMs. Only age over 65 years was statistically associated with an increased incidence. Overall, the incidence of SPMs was comparable to earlier estimations of SPMs in MM.",
keywords = "Journal Article",
author = "Firoozeh Sahebi and Simona Iacobelli and Giulia Sbianchi and Linda Koster and Didier Blaise and P{\'e}ter Rem{\'e}nyi and Russell, {Nigel H} and Per Ljungman and Guido Kobbe and Jane Apperley and Marek Trneny and Marta Krejci and Wieslaw Wiktor-Jedrzejczak and Sanchez, {James F} and Nicolaas Schaap and Cecilia Isaksson and Stig Lenhoff and Paul Browne and Christof Scheid and Wilson, {Keith M O} and Ibrahim Yakoub-Agha and {Gonz{\'a}lez Mu{\~n}iz}, Soledad and Stefan Sch{\"o}nland and Curly Morris and Laurent Garderet and Nicolaus Kr{\"o}ger",
note = "Copyright {\textcopyright} 2018. Published by Elsevier Inc.",
year = "2018",
month = may,
doi = "10.1016/j.bbmt.2018.01.006",
language = "English",
volume = "24",
pages = "930--936",
journal = "BIOL BLOOD MARROW TR",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "5",

}

RIS

TY - JOUR

T1 - Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents

AU - Sahebi, Firoozeh

AU - Iacobelli, Simona

AU - Sbianchi, Giulia

AU - Koster, Linda

AU - Blaise, Didier

AU - Reményi, Péter

AU - Russell, Nigel H

AU - Ljungman, Per

AU - Kobbe, Guido

AU - Apperley, Jane

AU - Trneny, Marek

AU - Krejci, Marta

AU - Wiktor-Jedrzejczak, Wieslaw

AU - Sanchez, James F

AU - Schaap, Nicolaas

AU - Isaksson, Cecilia

AU - Lenhoff, Stig

AU - Browne, Paul

AU - Scheid, Christof

AU - Wilson, Keith M O

AU - Yakoub-Agha, Ibrahim

AU - González Muñiz, Soledad

AU - Schönland, Stefan

AU - Morris, Curly

AU - Garderet, Laurent

AU - Kröger, Nicolaus

N1 - Copyright © 2018. Published by Elsevier Inc.

PY - 2018/5

Y1 - 2018/5

N2 - The advent of novel agents for multiple myeloma (MM) is cause for a re-examination of the incidence of second primary malignancies (SPMs). We examined the SPM rate in MM patients who were enrolled in the prospective observational CALM (Collaboration to Collect Autologous Transplant outcome in Lymphoma and Myeloma) study. Between 2008 and 2012, 3204 patients with MM underwent a first autologous hematopoietic stem cell transplantation. Plerixafor was used as a mobilizing agent for patients with poor (or potentially poor) stem cell mobilization as defined by the respective centers. A total of 135 patients developed SPMs, with a cumulative incidence of 5.3% (95% confidence interval, 4.4 to 6.3) at 72 months. Ninety-four patients developed solid tumors, 30 developed hematologic malignancies, and 11 developed an SPM of an unknown type. The cumulative incidence of known hematologic and solid malignancies were 1.4% and 3.6%, respectively, at 72 months. In a univariate analysis, use of radiotherapy, type of induction regimen, hematopoietic stem cell dose, poor mobilizer status, plerixafor use, and sex did not influence the cumulative incidence of SPMs. Only age over 65 years was statistically associated with an increased incidence. Overall, the incidence of SPMs was comparable to earlier estimations of SPMs in MM.

AB - The advent of novel agents for multiple myeloma (MM) is cause for a re-examination of the incidence of second primary malignancies (SPMs). We examined the SPM rate in MM patients who were enrolled in the prospective observational CALM (Collaboration to Collect Autologous Transplant outcome in Lymphoma and Myeloma) study. Between 2008 and 2012, 3204 patients with MM underwent a first autologous hematopoietic stem cell transplantation. Plerixafor was used as a mobilizing agent for patients with poor (or potentially poor) stem cell mobilization as defined by the respective centers. A total of 135 patients developed SPMs, with a cumulative incidence of 5.3% (95% confidence interval, 4.4 to 6.3) at 72 months. Ninety-four patients developed solid tumors, 30 developed hematologic malignancies, and 11 developed an SPM of an unknown type. The cumulative incidence of known hematologic and solid malignancies were 1.4% and 3.6%, respectively, at 72 months. In a univariate analysis, use of radiotherapy, type of induction regimen, hematopoietic stem cell dose, poor mobilizer status, plerixafor use, and sex did not influence the cumulative incidence of SPMs. Only age over 65 years was statistically associated with an increased incidence. Overall, the incidence of SPMs was comparable to earlier estimations of SPMs in MM.

KW - Journal Article

U2 - 10.1016/j.bbmt.2018.01.006

DO - 10.1016/j.bbmt.2018.01.006

M3 - SCORING: Journal article

C2 - 29339268

VL - 24

SP - 930

EP - 936

JO - BIOL BLOOD MARROW TR

JF - BIOL BLOOD MARROW TR

SN - 1083-8791

IS - 5

ER -